Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm VR-CAP as first-line treatment for marginal zone lymphoma
ChiCTR2000031704Phase 2Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib, rituximab, cyclophosphamide, doxorubicin and prednisone in marginal zone B-cell lymphoma (MZL), sponsored by Henan Cancer Hospital. Primary endpoint: 2-year progression-free survival. Started Apr 2020; status: recruiting.
02
Drugs
bortezomibrituximabcyclophosphamidedoxorubicinprednisone
03
Conditions
marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on ChiCTR2000031704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031704.